A Study To Assess The Pharmacokinetics Of Different Modified Release Formulations Of GSK221149 In Healthy Adult Subjects
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
PreTerm Labor (prior to 37 weeks gestation) is the largest single cause of infant morbidity
and mortality and is frequently associated with long-term disability. Oxytocin is a hormone
produced by the body during labor. GSK221149 is an experimental drug that will be used to
block the effects of oxytocin, and therefore pause or prevent contractions. In this study,
the pharmacokinetics of various modified release formulations of GSK221149 will be
investigated in healthy non-pregnant adult subjects.